



# CPDD 2021 Scientific Virtual Meeting

The Complete Guide

COMPREHENSIVE GUIDE

# 2021 SCIENTIFIC VIRTUAL MEETING

## TABLE OF CONTENTS

Letter From the President.....	3
CPDD Board of Directors.....	5
2021 Scientific Program Committee.....	6
General Information.....	7
Conference Speakers.....	9
Continuing Education Credits & Meeting Evaluation Information.....	10
2021 CPDD Award Winners.....	11
Presentation Information.....	13
2021 CPDD Travel Award Winners.....	14
Meeting Exhibitors & Grants.....	16
In Memoriam.....	17
2021 CPDD Donors.....	27
NIDA Mapping Patient Journeys Challenge.....	28
Save The Date.....	29
Save The Date.....	30

## Stacey Sigmon, Ph.D.

### President, CPDD

Dear friends and colleagues,

I'm very pleased to present to you our 83rd Annual Scientific Meeting of the College on Problems of Drug Dependence!

I expect you'll agree when I say that it's been a long year and I'd much rather be coming together in person to share science, laughs, delicious food and drinks in Montreal rather than sitting down for more virtual meetings. However, this week still provides a very important opportunity to share our work, learn new things, support our students and early career colleagues, and ensure that CPDD remains our thriving scientific home when the COVID pandemic is long behind us.



I would like to express my deep appreciation to all of the CPDD committee members, Board of Directors, Executive Committee and our Parthenon Management Group team who have worked tirelessly to create the great program represented in these pages. I'd especially like to thank Dr. Kelly Dunn and the entire Program Committee for their incredible efforts. Our program this year has more than 575 learning opportunities across a variety of Symposia, Mini-Symposia, Forums, Workshops, Oral Communications sessions and Posters. We have also created nine different themes or tracks to allow you to easily follow presentations aligned with your interests: Big Data and Epidemiology, Cannabis and Nicotine, Clinicians, Comorbidities, Medication Development, Opioids, Personalized Medicine, Preclinical, and Women and Children. Please also set your calendar to attend Dr. Sandro Galea's keynote address for our Presidential Symposium, which will be held on Monday, June 21 at 12:30 p.m. EDT. Dr. Galea is a physician, epidemiologist, author, and Dean of the Boston University School of Public Health. He will be speaking on the intersection of economics, politics, and the risk of substance use and its consequences. Big thanks also to our PMG team for the terrific interactive conference platform- it will definitely be more interesting and engaging than your typical Zoom session!

Please also join me in congratulating this year's [Joseph Cochin Young Investigator Award recipient, Dr. Cassandra Gipson-Reichardt](#), and Martin and Toby Adler Distinguished Service Award Recipient, Dr. Charles Gorodetzky. Additionally, we significantly expanded our Travel Awards to cover registration costs for this year's meeting for 109 attendees, and you can see a list of those recipients [here](#). These awardees will also remain eligible to apply for the same award (with travel benefits) in future years. Congratulations to all of our 2021 award recipients!


Please also don't forget to renew your membership! Our membership and conference registrations directly fund CPDD's programs, awards, and many opportunities for early career scientists. To ensure that we continue advancing substance use disorder research, I encourage you to renew your membership or donate to CPDD right away.

On a more serious note, this past year has also brought much sorrow to our community with the passing of many long-standing members of our CPDD family who were instrumental in shaping our field and ourselves. Many of CPDD's named awards have been created under sponsorship by our colleagues in the College. If you would like to establish an award in honor of a colleague, mentor or friend, please reach out to the Executive Office at [info@cpdd.org](mailto:info@cpdd.org).

Lastly, a look to the future and brighter year ahead of us. We are on track to come together for an in-person 2022 conference in Minneapolis, as well as CPDD's Advocacy Day in Washington DC in February. Go ahead and mark your calendars for these opportunities to reconnect with colleagues and share your work!

Thank you for the opportunity to serve as President of CPDD. It's been a privilege to represent the organization that has been my scientific home and family for the past 25 years.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Stacey Sigmon'.

**Stacey Sigmon, Ph.D.**  
President CPDD

# 2021 SCIENTIFIC VIRTUAL MEETING

## CPDD BOARD OF DIRECTORS

### President

**Stacey Sigmon, PhD**

*University of Vermont*

### Past President

**Elise Weerts, PhD**

*Johns Hopkins University School of Medicine*

### President Elect

**William Stoops, PhD**

*University of Kentucky*

### Treasurer

**Jack Bergman, PhD**

*McLean Hospital / Harvard Med School*

### Senior Project Manager

**Jesse Howard**

*Parthenon Management Group*

### Public Policy Officer

**Sandra D. Comer, PhD**

*Columbia University and NYSPI*

### Board Members

**Sudie Back, Ph.D.**

*Medical University of South Carolina*

**F. Ivy Carroll, PhD**

*RTI International*

**Ziva Cooper, PhD**

*UCLA Cannabis Research Initiative*

**Deborah S. Hasin, PhD**

*Columbia University*

**Amy Janes, PhD**

*McLean Hospital, Harvard Medical School*

**Jermaine Jones, PhD**

*Columbia University Vagelos College of Physicians and Surgeons*

**Frances R. Levin, MD**

*Columbia University and NYSPI*

**Wendy Lynch, PhD**

*University of Virginia*

**Geoffrey Mumford, PhD**

*American Psychological Association*

**Marco Pravetoni, Ph.D.**

*University of Minnesota Medical School*

**Beatriz Rocha, MD, PhD**

*Covance*

**James Rowlett, Ph.D.**

*University of Mississippi Medical School*

**Mark Smith, PhD**

*Davidson College*

**Dace Svikis, PhD**

*Virginia Commonwealth University*

**Erin Winstanley, PhD**

*West Virginia University*

# 2021 SCIENTIFIC VIRTUAL MEETING

## SCIENTIFIC PROGRAM COMMITTEE

**Kelly Dunn, Ph.D.**

*Johns Hopkins University School of Medicine*

**Matthew Banks, Ph.D., Pharm.D.**

*Virginia Commonwealth University*

**Eduardo Butelman, Ph.D.**

*The Rockefeller University*

**Diann Gaalema, Ph.D.**

*University of Vermont*

**Cassie Gipson-Reichardt, Ph.D.**

*University of Kentucky*

**Scott Hadland, M.D.**

*Boston University School of Medicine*

**Jermaine Jones, Ph.D.**

*Columbia University Irving Medical Center*

**Brian Kiluk, Ph.D.**

*Yale University School of Medicine*

**Stephen Kohut, Ph.D.**

*McLean Hospital, Harvard Medical School*

**Mikhail Koffarnus, Ph.D.**

*University of Kentucky, College of Medicine*

**Silvia Martins, M.D.**

*Columbia University*

**Justin Strickland, Ph.D.**

*Johns Hopkins University School of Medicine*

**Jennifer Tidey, Ph.D.**

*Brown University*

**Reagan Wetherill, Ph.D.**

*University of Pennsylvania*

**Kevin Freeman, Ph.D. (ex officio)**

*University of Mississippi Medical Center*



# 2021 SCIENTIFIC VIRTUAL MEETING

## GENERAL INFORMATION



### CREATE YOUR PERSONALIZED SCHEDULE

Login to your CPDD account to create your own personalized conference schedule! Once logged in, on the left side pane click, **"My Schedule"** and plan for the virtual conference by saving your favorite sessions that you don't want to miss!



### JOIN THE CONVERSATION

CPDD has gone social and we invite you to join the online conversation. Please be sure to follow/like the following CPDD social media accounts:

**@CPDDorg**



**@CPDDmembers**



**@CPDD**



And do not forget to use the hashtag **#CPDD21** if you post pictures or comments about the 2021 Scientific Virtual Meeting. *Tweet using #CPDD21 for your chance to win a \$100 Amazon Gift Card.*



### QUESTIONS

**If you have questions before or during the conference, we encourage you to:**

- 1) Use the Q&A feature to ask a question of the presenter or to contact AV support staff
- 2) Email [info@cpdd.org](mailto:info@cpdd.org) with additional questions or concerns or call (615) 432-0099.
- 3) Stop by the Help Desk & Speaker Ready Room, open daily.
- 4) Browse through the conference info.



### CPDD'S DISCLAIMER STATEMENT

Information obtained via CPDD channels, including webinars, conferences, websites, etc., is intended for only information and research purposes. CPDD cannot be held liable for the information consumed and may not reflect the opinions of CPDD or its members. The content and information shared should be used at the discretion of the consumer.

# 2021 SCIENTIFIC VIRTUAL MEETING

## PLENARY SPEAKER



### **George Koob, PhD**

*National Institute on Alcohol Abuse & Alcoholism (NIAAA)*

**Monday, June 21, 2021**

**10:00 AM EDT – 12:00 PM EDT**

George F. Koob, is Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as of January 27, 2014. He is also a Senior Investigator at the Intramural Research Program of the National Institute on Drug Abuse where he directs the Neurobiology of Addiction Laboratory in the Integrative Neurosciences Research Branch. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 750 peer reviewed papers and several books including the "Neurobiology of Addiction," a comprehensive treatise on emerging research in the field, and a 1 2021 CPDD Annual Scientific Meeting textbook for upper division undergraduates and graduate students called "Drugs, Addiction and the Brain." He has mentored 11 Ph. D students and over 80 post-doctoral fellows and mentored or co-mentored 11 K99's. He received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972. He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps' Committee on the Neurobiology of Addictive Disorders. Dr. Koob is the recipient of many honors, including membership in the National Academy of Medicine (USA) and award of the Legion of Honor (France).



## 2021 SCIENTIFIC VIRTUAL MEETING PLENARY SPEAKER



**Nora Volkow, M.D.**

*National Institute on Drug Abuse*

**Monday, June 21, 2021**

10:00 AM EDT – 12:00 PM EDT

Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs. Her studies have documented changes in the dopamine system affecting, among others, the functions of frontal brain regions involved with motivation, drive, and pleasure in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging and has published more than 720 peer-reviewed articles, written more than 100 book chapters and non-peer-reviewed manuscripts, and edited four books on neuroimaging for mental and addictive disorders.

# Continuing Education Credits

Attendees will be eligible to receive the credit hours listed below for attending the Conference. Psychologists will need to pass a posttest with a score of at least 75% and all attendees will need to complete the post-conference meeting evaluation.

**There will be a \$100.00 charge for registrants to obtain CE credits.** If you did not pay for the CE credits during registration, you will be prompted to do so during the evaluation process. Upon completion of the post-conference evaluation and attestation, your CE certificate will be emailed to you. Please note, this email will often go to spam. If you do not receive your certificate, please email [info@cpdd.org](mailto:info@cpdd.org).

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. Psychologists will also need to pass a posttest with a score of at least 75%. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

## Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and The College on Problems of Drug Dependence (CPDD). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Physicians (ACCME)

Credit Designation Statement – Live Content - Amedco LLC designates this live activity for a maximum of 21.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation Statement – Recorded/Enduring Content - Amedco LLC designates this enduring material activity for a maximum of 35.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The 21.25 live hours cannot also be claimed as enduring hours.

## Psychologists (APA)

Amedco LLC designates this live activity for a maximum of 21.25 Psychologist contact hours and the recorded/enduring activity for a maximum of 35.50 Psychologist contact hours. The 21.25 live hours cannot also be claimed as enduring hours.

## New York Board for Psychology (NY PSY)

Amedco is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031. Live activity maximum of 21.25 hours and recorded/enduring activity maximum of 35.50 hours. The 21.25 live hours cannot also be claimed as enduring hours.

**For more information visit the CE Center on the Virtual Meeting Platform: [Click Here](#)**

# Congratulations!



**Cassandra Gipson-Reichardt, Ph.D.**

*University of Kentucky*

*I am so grateful to receive the Cochin award this year. This award is meaningful to me because my colleagues, mentors, family, and friends have contributed so much to my career. To be recognized in this way truly is wonderful, and it is a reflection of the support I have received.*

Dr. Cassandra Gipson is a preclinical addiction neuroscientist, focusing on glutamatergic, cholinergic, ovarian hormone, and neuroimmune mechanisms involved in nicotine use and opioid/stimulant polysubstance use using rodent models. Dr. Gipson earned her Ph.D. in 2010 under the mentorship of Dr. Michael Bardo in the Psychology Department at the University of Kentucky prior to her postdoctoral fellowship with Dr. Peter Kalivas in the Neuroscience Department at the Medical University of South Carolina from 2010-2015. Dr. Gipson opened her independent laboratory as Assistant Professor in 2015 at Arizona State University, and was promoted to Associate Professor in 2020 at the University of Kentucky. Dr. Gipson has received numerous NIH grants as PI including a K99-R00, R01, R21, R03, and a R21-R33 with Dr. Bill Stoops. Further, she has published over 60 empirical and review papers in journals such as *Neuron*, *Proceedings of the National Academy of Sciences*, *eNeuro*, and *Addiction Biology*, as well as book chapters. Dr. Gipson has been a member of the CPDD program committee for four years, as well as the program committee for the Society for Research on Nicotine and Tobacco and the Education and Training Committee for the American College of Neuropsychopharmacology.



# Congratulations!



**Charles W. Gorodetzky, M.D., Ph.D.**  
*Consultant in Pharmaceutical Medicine*

*CPDD has been my scientific home for more than 55 years, through the three phases of my career; first in NIH (NIDA) intramural research, then in clinical development in the pharmaceutical industry, and finally as a consultant in pharmaceutical medicine. I am deeply grateful to the CPDD Board for the honor of this award. The fellowship, collegiality and support of CPDD has provided me more service than I have provided to the College.*

Dr. Gorodetzky obtained a B.S. at M.I.T. in 1958, then earned an M.D. at Boston University School of Medicine (1962) and a Ph.D. in Pharmacology from the University of Kentucky Medical Center (1975). He served for 21-years as a USPHS Officer in the NIH intramural research program at the NIDA (formerly NIMH) Addiction Research Center (ARC) in Lexington, KY; and he was the last Director of that facility (from 1981-84). His major research interests at the ARC were the clinical pharmacology and metabolism of drugs of abuse, with extensive work in the development and clinical application of urine screening methodology. He entered the pharmaceutical industry in 1984, and worked for the next 21 years in Clinical Development primarily of CNS drugs, with a continued interest in substance abuse and the development of drugs for its treatment (e.g. transdermal nicotine). During that period he held positions of increasing responsibility at several companies, with his last positions as Vice President at Hoechst Marion Roussel (and its predecessor, Marion Merrill Dow) and then at Quintiles. Since 2005 he has been actively engaged as a consultant in pharmaceutical medicine. He has served on FDA Advisory Committees as well as NIDA Review Groups and has been a frequent consultant to NIDA. He has attended all annual meetings of the CPDD since 1965, has served two elected terms on the CPDD Board, has headed the Rules Committee since the early 70's (as well as heading or serving on other CPDD committees), and has participated as an organizer and/or participant in most all of CPDD's annual meeting activities and presentation venues.

# 2021 SCIENTIFIC VIRTUAL MEETING

## VIRTUAL CONFERENCE

Access to the Virtual Meeting Platform and recordings will be available through July 31, 2021 for all attendees. Members will have access to all recordings through December 31, 2021.

**If you have questions before or during the conference, we encourage you to:**

- 1) Use the Q&A feature to ask a question of the presenter or to contact AV support staff
- 2) Email [info@cpdd.org](mailto:info@cpdd.org) with additional questions or concerns. Calling the CPDD Executive Office is not advised as the response time may be delayed during the conference.
- 3) Stop by the Help Desk & Speaker Ready Room, open daily.

## POSTER SESSIONS

Enter the e-poster gallery to access the virtual poster session and connect with the presenters! Video icons on the poster images for the poster session have been turned on to allow you to engage with the presenter via video chat. If you see the video camera image, the presenter is available for a live discussion. You can also post a question or leave a comment on the poster's discussion board! Filters on the left side of the screen will allow you to filter to only the posters being presented.

Each poster session has been grouped by topic on the agenda: you can also filter by these topics in the Poster Gallery:

**Alcohol, Cannabis/Cannabinoids, Human, Nicotine/Tobacco, Opiates/Opioids, Polydrug, Stimulants**

### Monday, June 21

3:00 PM – 4:00 PM EDT

Virtual Poster Q&A Session 1

### Tuesday, June 22

3:00 PM – 4:00 PM EDT

Virtual Poster Q&A Session 2

### Wednesday, June 23

3:00 PM – 4:00 PM EDT

Virtual Poster Q&A Session 3

### NIDA International Forum Poster Gallery

NIDA International Forum Posters will be available throughout the entire conference.

# 2021 SCIENTIFIC VIRTUAL MEETING

## CPDD TRAVEL AWARD WINNERS

### STEPHEN G. HOLTZMAN TRAVEL AWARD FOR PRECLINICAL INVESTIGATORS

Fernando de Moura, Ph.D.

### CPDD INTERNATIONAL AWARD

Anees Bahji  
Gayatri Bhatia  
Afolabi Oyapero  
Suzaily Wahab

### CPDD PRIMM-SINGLETON MINORITY TRAVEL AWARD

Emmanuel Alvarez  
Mehreen Arif  
Coralee Perez-Pedrogo  
Bryan Benitez  
Whitney Cordoba-Grueso  
Edda Rodriguez

### F.O.R.C.E. TRAVEL AWARD

Laura Brandt  
Irene Pericot-Valverde

### CPDD TRAVEL AWARD FOR EARLY CAREER INVESTIGATORS

Gema Aonso-Diego  
Amelia Bailey  
Emmanuelle Baillet  
Patrick Brown  
Katina Calakos  
Sierra Castedo de Martell  
Nina Christie  
Sarah Clingan  
William Craft  
Morgan Crowley  
Ayomide David  
Graham DiGuseppi  
Julien Dodu  
Dalton Edwards  
Andrew Fares  
Zhe Fei  
David Fink  
Ewa Galaj  
Erik Garcia  
Grant Glatfelter

Rachel Hoopsick  
Jennifer Hoots  
Erin Horne  
Raagini Jawa  
Bernard Johnson  
Ariana Johnson  
Luisa Kcomt  
Shailesh Khatri  
Emanuel Krebs  
Jessica Kulak  
Pooja Lagisetty  
Laura Lambert  
Juhan Lee  
Huajun Liang  
Kelsey Lucerne  
Sarah Lynn  
Daniel Martins  
Kristen McLaurin  
Christina Merritt  
Barrett Montgomery  
Catherine Moore  
Lauren Nguyen  
Stephanie Parent  
Emily Peck  
Daria Piacentino  
Stephen Robertson  
Kelly Sagar  
Karl Schmidt  
Paige Shaffer  
Vinita Sharma  
Jessica Sharp  
Justin Shepherd  
Kelsey Simpson  
Ashley Smith  
Kyle Snyder  
Ryan Sullivan  
Forrest Toegel  
Devin Tomlinson  
Richa Tripathi  
Helena Valente  
Alyssa Vanderziel  
Kainan Wang  
Heather Ward  
Rhiannon Wiley



# 2021 SCIENTIFIC VIRTUAL MEETING CPDD TRAVEL AWARD WINNERS

## **NIDA DIRECTOR'S TRAVEL AWARD**

Angel Algarin  
Trent Bullock  
Danielle Davis  
Teresa DeAtley  
Michelle Doyle  
Alice Ely  
Nicole Fitzgerald  
Brianna George  
Priscila Gonçalves  
Sarah Gutkind  
Zachary Mannes  
Nathaniel Moxley-Kelly  
Alexandra Palmisano  
Justin Strickland  
Andre B. Toussaint  
Neil Varshneya  
Noel Vest  
Heather Webber  
Alison Wakeford

## **NIDA WOMEN & SEX/GENDER JUNIOR INVESTIGATOR TRAVEL AWARD**

Janna Ataiants  
Elizabeth Charron  
Alba Gonzalez-Roz  
Erin Maher  
Erin Martin  
V́ctor Mart́nez-Loredo  
Hannah Mayberry  
Elisa Pabon  
Jobe Ritchie  
Pedro Rodriguez Rivera  
Joy Scheidell  
Drew Townsend

## 2021 SCIENTIFIC VIRTUAL MEETING

*Thank you* TO OUR EXHIBITORS!

**Pinney** Associates



---

## 2021 SCIENTIFIC VIRTUAL MEETING SPONSORS

CPDD would like to acknowledge the generosity of the following companies whose sponsorships have contributed to the overall quality of this meeting:

**Pinney** Associates



Funding for this conference was made possible (in part) by 5 R13 DA 013192 - 15 from the National Institute on Drug Abuse

*The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.*

## In Memoriam

### Reginald V. Fant, Ph.D.

#### 2020



**Dr. Reginald V. Fant ("Reggie")** died unexpectedly Sunday, September 27, following complications of a stroke. He was the Director of Clinical Pharmacology and Abuse Potential Assessment at PinneyAssociates (PA), in Bethesda, Maryland, where he worked for over 23 years. He led many of PA's abuse potential assessments of medicines in development. His efforts contributed to new medicines for treating addiction, anxiety, depression, epilepsy, pain, ADHD, sleep disorders, Parkinson's Disease, and many more, and involved conventional medicines as well as therapeutic applications of cannabinoids, psychedelics and dietary supplements such as kratom. His work was key in dozens of new drug filings to the FDA and led to more than 75 scientific articles.

Born in Thibodaux, Louisiana, Dr. Fant was awarded his BA in psychology at Nichols State University, in 1989. After achieving his PhD in experimental psychology from the University of Southern Mississippi in 1993, he was awarded a post-doctoral fellowship at Johns Hopkins University in the Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, in the School of Medicine under the direction of Professor Maxine Stitzer, along with Professors George Bigelow and Roland Griffiths. This was followed by his recruitment to the Biology of Dependence and Abuse Potential laboratory of the Intramural Research Program of the National Institute on Drug Abuse (NIDA) in 1995, where he worked under the direction of Drs. Jack Henningfield and Wallace Pickworth. He was recruited by and welcomed to PinneyAssociates in 1997.

Dr. Fant was distinguished by his thoughtful and creative approaches to understanding the potential addiction and abuse risks, and potential medical and public health benefits of new medicines so they could be properly regulated based on their potential benefits and risks. His contributions helped advance public health both nationally and globally. His work included studies contributing to FDA's regulation of tobacco and other nicotine delivering products such as cigarette substitutes and medicines for treating tobacco dependence. His passing leaves an enormous void at PinneyAssociates, and in the field of abuse potential assessment more broadly.

His Louisiana roots and family were an important part of his daily life. His passions included weightlifting, gardening and cooking. He was an especially cherished friend and colleague by his extended family at PinneyAssociates and Johns Hopkins. We will never forget his warmth and kindness, his sense of humor, or his easy-going spirit. He will be sorely missed.

## In Memoriam

### Nancy E. Suchman, Ph.D.

#### 2020



**Nancy E. Suchman, Ph.D.**, 63, died peacefully at home on December 25, 2020 with her husband at her side after a courageous battle with an aggressive cancer. At the time of her death, Nancy was an Associate Professor in the Department of Psychiatry and the Child Study Center who had made significant contributions to the science of addiction, parenting, and child development.

After spending much of her childhood and adolescence in the New York City area, Nancy left home for Cornell University where she earned a bachelor's degree in psychology in 1979. Following graduation, she spent her early adult years leading high-adventure trips for Outward Bound, a national outdoor education program. After realizing, in her sentiments, that she could not live off the land, neither literally nor figuratively, she returned to school and completed a master's degree in the sociology of education at Syracuse University in 1986 and then a doctoral degree in counseling psychology at Colorado State University in 1994 where, given her love of the outdoors, she continued to spend time pursuing high adventure in the Rocky Mountains.

Nancy returned to the Northeast to complete her predoctoral internship in clinical psychology at the VA Connecticut Healthcare System and then came to the Department of Psychiatry as a postdoctoral fellow in 1994 to join a new child and family research team being developed by Suniya Luthar under the mentorship of Bruce Rounsaville. It was here that she met Tom McMahon, the third psychologist in this nascent research group. Together, the three of them worked collaboratively for 10 years pursuing a series of related research projects with parents in addiction treatment and youth at risk to misuse alcohol and drugs.

With Suniya Luthar, Nancy developed a psychotherapy group for women struggling with drug addiction. This was one of the first clinical interventions grounded in an empirical conceptualization of the complex needs mothers bring to addiction treatment. Once she had an academic niche, Nancy devoted her career to the study of parenting as a critical issue in the lives of mothers, and fathers, affected by drug addiction. With the untimely death of Bruce Rounsaville, Linda Mayes at the Child Study Center became Nancy's primary mentor as her work began to focus more clearly on the needs of women parenting infants and preschool children in the context of drug addiction. Over more than 25 years, Nancy was the principal investigator for a series of research training and independent research grants funded by the National Institute on Drug Abuse (NIDA).



Much of her research was conducted in collaboration with The APT Foundation, a private-nonprofit, university-affiliated provider of addiction services in the greater New Haven area. Nancy's most significant academic contribution, and the one most meaningful to her, was the development of *Mothering from the Inside Out*, an attachment-based parent intervention. This empirically based individual psychotherapy is designed to help mothers grappling with addiction and other threats to effective parenting develop the capacity for reflective functioning in their relationships with their children. Over more than 15 years, she partnered with Cindy DeCoste, her project director, and a long list of co-investigators, consultants, clinicians, and research assistants to develop and test this clinical intervention. As this novel intervention captured the attention of the research community interested in the impact of addiction on parenting, she began an academic tour to speak, teach, and consult, not just in this country, but in Finland, South Africa, Australia, Canada, France, Italy, Germany, and the United Kingdom.

In addition to her peer-reviewed publications, Nancy was the principal editor of *Parenting and Substance Abuse* with Linda Mayes and Marjukka Pajulo of the University of Turku in Finland. This volume, published by Oxford University Press, quickly became the definitive professional reference on addiction, parenting, and parent intervention.

Over the years, Nancy made significant contributions to the personal and professional development of others. Among them are the mothers and children who have benefitted, directly and indirectly, from her clinical insights and the research assistants, graduate students, professional trainees, addiction counselors, and researchers who benefitted from her generous giving of her time and tutelage. On July 31, 2020, she was very pleased to see many of those people during a special grand rounds and reception organized by the Department of Psychiatry and Child Study Center to recognize her contributions to research, teaching, and service delivery.

When not at work, Nancy loved everything outdoors. Throughout her adult life, she was an enthusiastic hiker, cyclist, canoer, and cross-country skier. She also enjoyed gardening, reading, traveling, and spending time with family and friends. A long-time resident of Hamden, she especially loved hiking in Sleeping Giant State Park, often followed by a visit to Wentworth's Homemade Ice Cream Shop.

Nancy is survived by her husband, Lionel Rigler; her brother, Anthony Suchman and his wife, Lynne Feldman; and her sister, Olivia Suchman. A devoted aunt, she is also survived by her nieces and nephews, Alexandra Suchman, Julian Suchman, Matthew Milner, and Danielle Milner. Her warm, compassionate, generous, and vibrant nature will be present in the hearts and minds of family, friends, colleagues, and mothers around the world for many years to come.

## In Memoriam Kathleen M. Carroll, Ph.D. 2020



**Kathleen (Kathy) M. Carroll, PhD**, a clinical scientist in the Yale Department of Psychiatry who made seminal contributions to improving treatments for addiction, died unexpectedly after a brief illness on December 28, 2020. She was 62 years old. At the time of her death, Dr. Carroll was the Albert E. Kent Professor of Psychiatry, Yale School of Medicine, and the Director of the Psychosocial Research in the Division on Addictions. Kathy possessed a rare blend of brilliance, generosity, and humility that propelled a career spanning over 30 years in addiction treatment research at Yale. She graduated *summa cum laude* from Duke University, received her PhD in clinical psychology and neuropsychology in 1988 from the University of Minnesota, and completed her pre-doctoral training at the Yale School of Medicine's Division of Substance Abuse. Following a brief stint as Instructor in Neurology at Harvard Medical School, she joined the faculty at Yale in 1989 as Assistant Professor of Psychiatry. Working closely with Dr. Bruce Rounsaville, she helped establish and subsequently led the Psychotherapy Development Center (PDC), the National Institute on Drug Abuse's (NIDA's) only funded Center of Excellence devoted to behavioral therapies research. Through Dr. Carroll's leadership, the PDC became one of the most important sources of addiction treatment development and dissemination over the past 25 years, improving the methodological rigor of clinical trials research and leading to multiple clinical innovations that have impacted the lives of many struggling with addiction. Officially ending in 2020, the PDC produced over 1,500 peer-reviewed publications and launched the careers of dozens of independent investigators. Dr. Carroll also served as a Principal Investigator of NIDA's Clinical Trials Network, a partnership between NIDA, treatment researchers and community providers to work toward new treatment options in community-level clinical practice.

The depths of her contribution to the field of addiction are unparalleled. She has been a Principal Investigator on over 100 research projects funded through NIH, with funding amounts totaling over \$76 million. She authored or co-authored over 330 articles in peer-reviewed publications, with over 50 chapters in major textbooks, along with several books and published manuals. Her Cognitive Behavioral Therapy (CBT) manual for cocaine use disorders has been translated to over 14 languages and implemented worldwide. Among the defining accomplishments of her career has been broader recognition of the efficacy, safety, and durability of behavioral therapies.



She helped establish the Stage Model of Behavioral Therapies Development that facilitated important advances by defining stages of science for behavioral therapies development, from pilot testing of novel approaches translated from basic clinical science ("Stage 1") to efficacy testing via randomized clinical trials ("Stage 2") to effectiveness research based in community settings (Stage 3"). This required a set of methodological advances (e.g., systemization of interventions in manuals, development of fidelity rating systems, therapist training strategies) to which she made multiple contributions. She received a NIH MERIT award for her work which led to the development of an effective web-based version of CBT ("CBT4CBT"), now validated in eight independent trials. CBT4CBT became one of the first evidence-based computerized interventions for a range of substance use disorders and is currently being adapted and implemented for various co-occurring conditions.

Dr. Carroll served on several journal editorial boards, advisory boards, and NIH scientific review panels, too numerous to list. Most recently, she was an invited member of the National Academy of Medicine's committee on medications to treat opioid use disorders and was a major author of its influential consensus report, *"Responding to the Opioid Crisis: Medications Save Lives."* Dr. Carroll received many prestigious awards but being honored in September of this year at the 50<sup>th</sup> anniversary celebration of the APT Foundation, where she conducted much of her research, was among the most meaningful to her. This award highlighted not only her research contributions but her mentorship and relationships with others, to which she was truly committed. According to long-time collaborator, Charla Nich, "we were blessed to be able to give Kathy a message just three months ago about our gratitude for her scientific integrity, brilliance, courage, strength, radical acceptance, and love personified." Ayana Jordan, MD, PhD, a current mentee noted, "Her ability to lead compassionately and lift others while climbing is indeed a gift from the creator." Brian Kiluk, PhD, another long-time mentee, described her as "the embodiment of a true mentor – someone who both teaches and guides others on their career path, but also serves as a shining example for what others aspire to be."

Dr. Carroll's tremendous academic and scientific accomplishments are dwarfed by her kind, generous, and playful spirit. She had an amazing ability to find joy in everyday situations, especially in life's most difficult moments. She loved swimming, art history, architectural history, hiking, and reading. Kathy was an expert on the works of Shakespeare and opera. She also had a fine sense of humor and loved a good prank. She was a lifelong progressive with great compassion for social justice and coupled anti-racist principles with her recent academic work on identifying and addressing racial and ethnic disparities in substance use treatment outcomes.

Kathy maintained a decades old relationship with Christian Community Action (CCA) in New Haven and contributed annually through efforts to provide school clothing, Christmas gifts, and Easter baskets for children living in emergency housing. From her hospital bed one week prior to falling critically ill, Kathy reached out to CCA caseworkers to make sure that all the homeless children were cared for and donated electronically toward that effort.

## In Memoriam Alan Gintzler, Ph.D. 2021



**Alan Gintzler, PhD**, CPDD member since 1993, died Saturday, March 20th, after struggling with cancer for the last several months. Our condolences go to Alan's wife, Ellen Cohen, and their daughter Ariella, and all other relatives and friends.

Alan is remembered as a person of great dedication to his family, who sought the best for everyone, and who treasured every moment he could spend outdoors in the natural world. He is also remembered for his work as a professor and research scientist at Downstate Medical Center and his outstanding mentorship to his students.

This page describes his professional pursuits:

<https://www.rfsuny.org/About-Us/Leadership/Board-of-Directors/Dr-Alan-R-Gintzler/>



## In Memoriam

### Mary Jeanne Kreek, Ph.D.

#### 2021



It is with great sadness that we share the news of the passing of Dr. Mary Jeanne Kreek on March 27, 2021. Dr. Kreek was a pioneer in Substance Use Disorder research and an instrumental leader of The College on Problems of Drug Dependence, Inc. (CPDD), having served the College in numerous roles since 1982.

Mary Jeanne Kreek, M.D. was a graduate of Wellesley College where she received Durant Scholar honors in chemistry and biology, and the Columbia University College of Physicians and Surgeons where she received an M.D. degree and the Borden Award for research. During her postgraduate work at Cornell University-New York Hospital Medical Center in internal medicine, gastroenterology and neuroendocrinology, Dr. Kreek joined the Rockefeller Institute in 1964, as a research fellow with the late Dr. Vincent P. Dole and Dr. Marie Nyswander. While there, Dr. Kreek conducted the initial studies on the long-acting opioid agonist, methadone, in the chronic management of heroin addiction, leading to the development of the first effective pharmacotherapy for the treatment of opioid addiction. This research led to a number of prospective long-term studies of the safety and the physiological effects of methadone and the medical status of heroin dependent individuals before and during treatment.

Dr. Kreek was Professor and Head of Laboratory, the Laboratory of the Biology of Addictive Diseases at The Rockefeller University, and Senior Physician of The Rockefeller University Hospital in New York City. She was also Principal Investigator and Scientific Director of an NIH-NIDA Research Center. Dr. Kreek has been a recipient of the NIH-NIDA Senior Research Scientist Award since its inception in 1978. She has served on several NIH Study Sections, FDA Advisory Groups, the NIDA National Advisory Council, and as a charter member of the NIH Peer Review Oversight Group.

By the early 1970s, her work increasingly focused on the molecular and neurobiological basis of Substance Use Disorder. Dr. Kreek's research efforts led to publications as author or co-author of over 400 scientific reports, concept papers, and review articles. Over the many decades of her dedication to the treatment and research in Substance Use Disorder, Dr. Kreek received numerous awards, too numerous to mention. In 1998, she received the Special Recognition Award for Research in the Science of Addiction, Executive Office of the United States President. She has also received several Honorary Degrees.

As a pioneer in Substance Use Disorder research, she was an outstanding leader of The College on Problems of Drug Dependence, having served the College in numerous roles since 1982. Over the years, Dr. Kreek served the College as follows:

- Executive Committee, 1982-1994
- President-Elect, 1984-1985
- Program, Travel Award Fellowship Committee, 1983-1994
- President, 1985-1987
- Past President, 1987-1989
- Membership Chair, 1989-1991
- Program Chair, 1990-1995
- Past Program Chair, 1995-1998
- Nominating Committee, 1997-1998
- Long-Range Planning Committee, 1998-2003
- Awards Committee 2001-2003- Program Committee, 2001-2004
- Board of Directors, 2010-2014
- Awards Committee, 2012-2016
- Long-Range Planning Committee, 2014-2020

Over her career of nearly six decades, Dr. Kreek received numerous awards, and, at CPDD, she was the 1999 recipient of the Nathan B. Eddy Memorial Award, the most prestigious award presented by the CPDD which acknowledges outstanding research efforts that have advanced our knowledge of drug dependence. In 2005, she was the recipient of the Marian W. Fischman Lectureship Award which recognizes the contributions of an outstanding woman.

Dr. Kreek's research has led to medical treatments for various diseases of addiction and has taught us much about the molecular and genetic underpinnings of drug cravings. In addition, she has been championing the implementation of drug treatment programs worldwide.

She has been dedicated to spreading the use of therapy for Substance Use Disorder, traveling from Sweden to Hong Kong. and mainland China, Italy and Israel as well as many other countries to help in its implementation. She was a generous teacher and mentor to young physician-scientists around her and she was particularly passionate about supporting other women.

By molecular, cell biological, neurochemical, behavioral and basic clinical research and human genetics studies, she documented the role of the endogenous opioid system in cocaine, alcohol, and heroin addiction. With her colleagues, Dr. Kreek examined gene expression changes in rodents that are given a drug of abuse, or are allowed to self-administer it, to study how this exposure impacts the brain's neurochemistry, neurobiology, and circuitry, and to identify targets for potential new treatments. Her lab also studied the epigenetic, physiologic, and behavioral effects of drug self-administration on the endogenous opioid system and related signaling networks. They performed microdialysis in rats and mice for dynamic studies of neurotransmitter release and peptide processing in the brain.



More recently, her lab identified more than 100 changes in the DNA code associated with addiction not only to opioids but also to cocaine, alcohol, and marijuana. She found that several of these changes were also associated with atypical responses to stress, potentially leading to an increased tendency to become addicted. Her work on the genetic changes linked to addiction has ongoing implications for developing new ways to recognize and treat addictions to a number of different substances.

Dr. Kreek was also particularly passionate about conquering stigma in Substance Use Disorder. She frequently spoke about addictions as diseases of the brain which respond to treatment and not criminal behaviors or weaknesses. In a recent interview, she said, "There is no longer any doubt that drug addiction boils down to neurobiology and I remain optimistic even though the use of medication to treat it still faces many hurdles. It's one step at a time. One hundred years ago, cancer was considered evil and dirty. It meant something was wrong with your family—people didn't want to admit they had it. So, we have had stigmas before and they're not easy to overcome. But the science helps immensely to convince people of the reality of the situation."

Kreek is survived by two children: daughter Dr. Esperance Schaefer, with son-in-law Karl Welday and grandchildren Robert and Francine; and son Robert Schaefer, with daughter-in-law Heather Fain Schaefer and grandchildren Merrill and William. Her husband of 48 years, Robert Schaefer Sr., who was a gastroenterologist and an associate professor at Weill Cornell Medicine, died in February 2018.

Dr. Mary Jeanne Kreek will be remembered with great respect by the national and many international members of the College with whom she interacted and who have honored her in many ways not only for the outstanding science that she was willing to share but also the compassion and respect that she demonstrated with regard to those individuals with Substance Use Disorder.

## In Memoriam Martin Y. Iguchi, Ph.D. 2021



Martin Y. Iguchi, a senior behavioral scientist at the RAND Corporation and a professor at Pardee RAND Graduate School, died June 5, 2021.

Most recently he was lead professor for assessment at Pardee RAND and the program director for the school's redesign. At RAND he worked on the use of smart phones to provide remote delivery of contingency management, cognitive behavioral therapy, and coaching to persons with alcohol use disorder and on Medicaid in Vermont.

His other recent work examined quality of life and retirement/legacy planning in aging performing artists; sexual transmission of HIV from and among drug users to non-drug users; barriers to drug abuse treatment entry among Asian and Pacific Islanders; low-frequency injection drug users; and HIV-related risk behaviors in men who have sex with men (MSM).

Iguchi was a fellow of the American Psychological Association (APA) and recipient of the APA Presidential Citation (2019); elected member of APA's Board of Scientific Affairs and APA's Board of Professional Affairs; BOD for APA's Division 50; member of the National Institute on Drug Abuse's Center Grant Research Review Committee; member, BOD, College on Problems of Drug Dependence; co-chair, Scientific Working Group on MSM and Sexual Minorities, District of Columbia Developmental Center for AIDS Research; and program area co-director, Barriers to Care, UCLA AIDS Institute.

Iguchi was a senior editor for *Addiction* and on the following editorial boards: *Journal of Drug Issues*; *Drug and Alcohol Dependence*; *Journal of Drug Policy Analysis*; *Retrovirology: Research and Treatment*; *Clinical Psychology: Science and Practice*; and *Journal of Cannabis Research*.

His former leadership roles included director of the RAND Drug Policy Research Center; chair of Community Health Sciences, UCLA School of Public Health; and Dean, Nursing and Health Studies, Georgetown University.

Iguchi earned his Ph.D. and M.A. in experimental psychology from Boston University.



# Thank You!

CPDD would like to give a special thank you to all of our donors. With your help, we will continue to grow and move the science community forward.

**Sarah Heil PhD**

University of Vermont

**Denise Hien PhD**

Rutgers Center of Alcohol & Substance Use Studies, Graduate School of Applied and Professional Psychology

**Frederic Hopf PhD**

Indiana University

**Scott Lukas PhD**

McLean Hospital, Harvard Medical School

**John Mendelson MD**

Ria Health

**Jason Paris PhD**

University of Mississippi

**Marco Pravetoni PhD**

University of Minnesota Medical School

**Stacey Sigmon PhD**

University of Vermont

**Judith Tsui MD, MPH**

University of Washington

**Mark Smith PhD**

Davidson College

**Maxine Stitzer PhD**

Johns Hopkins University School of Medicine

**William Stoops PhD**

University of Kentucky

**John Strang Prof.**

King's College London

**Dace Svikis PhD**

Virginia Commonwealth University

**Annie Umbricht MD**

Johns Hopkins University School of Medicine

**Frank Vocci PhD**

Friends Research Institute

**Erin Winstanley PhD**

West Virginia University



## Mapping Patient Journeys in Drug Addiction Treatment

The National Institute on Drug Abuse (NIDA), one of the components of the National Institutes of Health (NIH), is announcing the “**Mapping Patient Journeys in Drug Addiction Treatment**” Challenge. The Challenge goal is to inspire the depiction of actionable patient journey maps that might further the understanding of the obstacles that patients face in getting treatment for drug addiction, particularly while our country is in the middle of an ongoing opioid crisis. NIDA invites the solvers to capture specific points during the patient journey where patients encounter the most difficulty, enabling NIDA to focus new research efforts into alleviating those areas of difficulty in patients’ drug addiction treatment journeys.



The Challenge will offer up to three awards for first, second, and third place entries of \$50,000, \$30,000, and \$20,000 each, respectively. **The Challenge total purse is up to \$100,000.**

**What is a patient journey?** A patient journey is the ongoing sequence of care events which a patient follows from the point of access into the health system, continuing towards diagnosis and care, and ending in outpatient care or recovery. It can be visualized as an ongoing interaction of care events occurring between the patients and healthcare providers. This journey can include many interconnected activities, ranging from the early education and awareness phase (for example, going online and searching for information about symptoms) to finding a clinic or provider, producing insurance or payment, interacting with a physician or other healthcare providers, and finally, appointment follow-ups and reminders for continued care. At the core of health care are the patients and the delivery of services that make them feel safe, comfortable, and ultimately result in improvements to their medical condition. However, for many SUD patients, the health care experience can be challenging, confusing, and inconsistent.

Given the complexity and high number of interdependencies that exists within SUD services, NIDA is eager to challenge the SUD provider and patient communities to depict patient journey maps that are both comprehensive and accessible. If you are someone with access to, experience with, and knowledge of the SUD patient community, you are invited to create a patient journey map throughout SUD illness to recovery so that NIDA can better understand positive and negative patient interactions with the health system.



### Key Dates

- Submission Start: April 22, 2021 12:00 AM ET
- Submission End: September 22, 2021 11:59 PM ET



**PinneyAssociates is Proud to  
Participate in and Support the  
College on Problems  
of Drug Dependence  
83rd Annual  
Virtual Scientific Meeting**

**June 21 – 24, 2021 | CPDD.org**

*[www.PinneyAssociates.com](http://www.PinneyAssociates.com)*





# Save the Date

**CPDD 2022 Scientific Meeting**

Hilton Minneapolis

June 11-15, 2022



**The College on Problems  
of Drug Dependence**